Physician profile
Suzanne L Fox
NPI 1104816438
$1,325.40
in general payments reported to CMS, 2019-2025
19 companies · $114 in 2025
The $114 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $52.49 · 2021: $140 · 2022: $199 · 2023: $322 · 2024: $341 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $358.85 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $319.69 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $196.82 | 2019-2024 | Jornay Pm |
| Corium, LLC | $78.90 | 2023-2025 | Azstarys |
| Kaleo, INC. | $54.32 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.98 | 2020-2021 | |
| Pfizer INC. | $38.75 | 2022-2023 | |
| Glaxosmithkline, LLC. | $30.51 | 2021-2022 | |
| Tris Pharma INC | $25.82 | 2019 | |
| Sanofi Pasteur INC. | $25.78 | 2023 | |
| Collegium Pharmaceutical, INC. | $21.40 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $19.71 | 2025 | |
| Shire North American Group INC | $18.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.54 | 2024 | Zoryve |
| Vertical Pharmaceuticals, LLC | $16.46 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $16.23 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $14.63 | 2024 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $14.05 | 2019 | |
| Merck Sharp & Dohme LLC | $13.63 | 2024 | Vaxneuvance, Vaqta, Vaxelis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.